Advances in Immunotherapy for Genitourinary Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 30649
Special Issue Editor
Interests: bladder cancer; immunotherapy; urothelial carcinoma; biomarkers
Special Issue Information
Dear Colleagues,
Over the last few years, immunotherapy has become an increasingly attractive treatment modality in many solid tumors, including genitourinary malignancies. Novel immunotherapy strategies offer a promising approach to improve the overall survival and quality of life outcomes for cancer patients. The discovery of checkpoint inhibitors has significantly changed the field of cancer immunotherapy. However, more studies will be required to understand how to manipulate the immune system to improve anti-tumor activity by combining checkpoint inhibitors with other immune co-stimulatory therapies and/or conventional cancer therapies. In this Special Issue, experts in the field will review and present advances in understanding and modulating the immune microenvironment of genitourinary malignance.
Prof. Amirali Salmasi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genitourinary malignancy
- immunotherapy
- bladder cancer
- prostate cancer
- kidney cancer
- urothelial carcinoma
- renal cell carcinoma
- checkpoint inhibitors